Eocene GLMD Stock
Eocene Price Chart
Eocene GLMD Financial and Trading Overview
| Eocene stock price | 4.63 USD |
| Previous Close | 3.83 USD |
| Open | 3.91 USD |
| Bid | 2.66 USD x 200 |
| Ask | 5.05 USD x 200 |
| Day's Range | 3.82 - 4.63 USD |
| 52 Week Range | 3.29 - 13.2 USD |
| Volume | 301.16K USD |
| Avg. Volume | 63.56K USD |
| Market Cap | 4.95M USD |
| Beta (5Y Monthly) | 0.666 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -14.29 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GLMD Valuation Measures
| Enterprise Value | -7066382 USD |
| Trailing P/E | N/A |
| Forward P/E | -4.495146 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.27383485 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | N/A |
Trading Information
Eocene Stock Price History
| Beta (5Y Monthly) | 0.666 |
| 52-Week Change | -68.21% |
| S&P500 52-Week Change | 15.30% |
| 52 Week High | 13.2 USD |
| 52 Week Low | 3.29 USD |
| 50-Day Moving Average | 4.33 USD |
| 200-Day Moving Average | 5.17 USD |
GLMD Share Statistics
| Avg. Volume (3 month) | 63.56K USD |
| Avg. Daily Volume (10-Days) | 68.7K USD |
| Shares Outstanding | 1.07M |
| Float | 974.74K |
| Short Ratio | 0.05 |
| % Held by Insiders | 3.03% |
| % Held by Institutions | 1.89% |
| Shares Short | 4.66K |
| Short % of Float | 0.45% |
| Short % of Shares Outstanding | 0.44% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:8 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -30.18% |
| Return on Equity (ttm) | -68.20% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -11343000 USD |
| Diluted EPS (ttm) | -12.71 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 11.23M USD |
| Total Cash Per Share (mrq) | 11.22 USD |
| Total Debt (mrq) | 129K USD |
| Total Debt/Equity (mrq) | 1.01 USD |
| Current Ratio (mrq) | 4.162 |
| Book Value Per Share (mrq) | 16.908 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -8543000 USD |
| Levered Free Cash Flow (ttm) | -5274625 USD |
Profile of Eocene
| Country | United States |
| State | N/A |
| City | Ramat Gan |
| Address | 16 Abba Hillel Road |
| ZIP | 5250608 |
| Phone | 972 3 693 8448 |
| Website | https://galmedpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 3 |
Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Q&A For Eocene Stock
What is a current GLMD stock price?
Eocene GLMD stock price today per share is 4.63 USD.
How to purchase Eocene stock?
You can buy GLMD shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Eocene?
The stock symbol or ticker of Eocene is GLMD.
Which industry does the Eocene company belong to?
The Eocene industry is Biotechnology.
How many shares does Eocene have in circulation?
The max supply of Eocene shares is 1.07M.
What is Eocene Price to Earnings Ratio (PE Ratio)?
Eocene PE Ratio is now.
What was Eocene earnings per share over the trailing 12 months (TTM)?
Eocene EPS is -14.29 USD over the trailing 12 months.
Which sector does the Eocene company belong to?
The Eocene sector is Healthcare.
Eocene GLMD included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26333.04 USD — |
+0.96
|
5.66B USD — | 26283.11 USD — | 26431.22 USD — | — - | 5.66B USD — |
|
US Tech Composite Total Return
XCMP
US
|
32519.98 USD — |
+0.97
|
— — | 32458.33 USD — | 32641.23 USD — | — - | — — |
|
US Tech Capital Market Composite
RCMP
US
|
137.24 USD — |
+0.22
|
— — | 137.22 USD — | 139.48 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1293.65 USD — |
+0.07
|
— — | 1293.64 USD — | 1310.12 USD — | — - | — — |
- {{ link.label }} {{link}}
